ESMO 2023: A new immunotherapy, volrustomig, for the first-line treatment of advanced kidney cancer
Blocking the action of two proteins in cancer cells (PD-1 [...]
ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
Belzutifan plus cabozantinib combination shows promising results in kidney cancer
Kidney cancers often have mutations in a gene called the [...]
Does the time to start first-line treatment influence survival of patients with low risk kidney cancer?
Many patients with low-risk or favourable-risk kidney cancer may have [...]
EIKCS 2022: Debate about later-line treatments
At the 2022 European International Kidney Cancer Symposium (EIKCS) in [...]
Immunotherapy combinations in the first-line treatment of metastatic sarcomatoid kidney cancer
A recent study looked at the efficacy and safety of [...]
Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer
There is very little information on the effectiveness of sunitinib [...]
Nivolumab/cabozantinib combination approved in EU for first-line kidney cancer treatment
The European Commission has approved the use of the nivolumab [...]
ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer
Results from the phase 3 CLEAR study, presented at the [...]
Individualising first line treatment for advanced kidney cancer
In recent years, a number of new, effective treatments have [...]
